TESARO Announces Participation at Two Investor Conferences
21. Februar 2017 16:15 ET
|
TESARO, Inc.
WALTHAM, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences....
Tesaro to Announce Fourth-Quarter 2016 Financial Results on February 28, 2017
14. Februar 2017 16:05 ET
|
TESARO, Inc.
WALTHAM, Mass., Feb. 14, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its fourth-quarter 2016 financial results on Tuesday, February 28, 2017, after the close of the U.S....
Tesaro Announces Participation at Two Investor Conferences
02. Februar 2017 16:15 ET
|
TESARO, Inc.
WALTHAM, Mass., Feb. 02, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in two upcoming investor conferences....
Tesaro Announces Opening of Niraparib Expanded Access Program for U.S. Patients With Ovarian Cancer
17. Januar 2017 08:01 ET
|
TESARO, Inc.
WALTHAM, Mass., Jan. 17, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the opening of an expanded access program (EAP) in the...
TESARO Receives Complete Response Letter for Rolapitant IV from U.S. FDA
11. Januar 2017 23:30 ET
|
TESARO, Inc.
No concerns raised by FDA related to the rolapitant IV efficacy or safety profile and additional clinical studies are not requiredInvestor conference call and webcast scheduled for tomorrow at 8:30AM...
Tesaro Announces Priority Review Designation for Niraparib NDA
20. Dezember 2016 08:00 ET
|
TESARO, Inc.
Niraparib New Drug Application accepted for review by FDA with a PDUFA goal date of June 30, 2017Niraparib Expanded Access Program (EAP) expected to open in U.S. in January 2017 WALTHAM, Mass., Dec. ...
Tesaro Announces Participation in Three Investor Conferences
21. November 2016 16:05 ET
|
TESARO, Inc.
WALTHAM, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation in three upcoming investor...
TESARO Announces Pricing of Public Offering of Common Stock
15. November 2016 09:29 ET
|
TESARO, Inc.
WALTHAM, Mass., Nov. 15, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that it has priced an underwritten public offering of an aggregate of 1,750,000 shares of its common...
TESARO Announces Proposed Public Offering of Common Stock
14. November 2016 16:05 ET
|
TESARO, Inc.
WALTHAM, Mass., Nov. 14, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) announced today that it has commenced an underwritten public offering of 1,750,000 shares of its common stock. In...
TESARO Announces Third-Quarter 2016 Operating Results
03. November 2016 16:05 ET
|
TESARO, Inc.
Niraparib rolling NDA submission to FDA complete, MAA accepted for review by EMAPre-launch planning ongoing to support four potential product launches in 2017 across U.S. and EuropePositive Phase 3...